Latest Advances in Lung Cancer Research

The FDA granted orphan drug status to Quratusugene ozeplasmid, a promising gene-based therapy for small cell lung cancer, to expedite its development.

A recent multicenter study published in The Lancet highlights the promising efficacy of immunotherapy in advanced lung cancer patients.

The Monarch Platform robotic tool has revolutionized the way lung cancer is diagnosed and treated at Baptist Health. This cutting-edge technology provides a real-time, high-definition view of the airways, enabling doctors to identify and biopsy suspicious lung nodules with increased accuracy.

Scientists discover new link between air pollution and lung cancer, finding tiny particles trigger genetic changes, leading to new prevention and treatment opportunities.

Rybrevant plus chemo extends progression-free survival for newly diagnosed EGFR exon 20 patients, per study in Journal of Clinical Oncology.

A recent study sheds light on the challenges faced by black veterans when it comes to receiving timely referrals for lung cancer. The study, conducted by researchers from the University of Michigan and the VA Ann Arbor Healthcare System, examined the referral patterns for lung cancer among black and white veterans.

Dr. Steven Dubinett, member of LCFA’s Scientific Advisory Board, has been appointed as the new Dean of the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). In this role, Dr. Dubinett will oversee the medical school’s operations and work towards advancing its mission of excellence in education, research, and patient care.

Bristol-Myers Squibb’s CheckMate-9LA trial shows combining nivolumab, ipilimumab, and chemotherapy improves outcomes in advanced NSCLC patients.

A groundbreaking study has revealed that a new lung cancer pill significantly cuts the risk of death by 50%.

In a recent study, patients who took Keytruda before and after surgery had better results than those who only had surgery.

Severe asthma and lung cancer may be linked, according to a new study.